Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConcurrent Technologies Regulatory News (CNC)

Share Price Information for Concurrent Technologies (CNC)

Share Price is delayed by 15 minutes
Get Live Data
248.50    -1.50 (-0.60%)
Bid:
245.00
Ask:
252.00
Spread: 7.00 (2.857%)
Market Cap: £225.74m
CNC Live PriceLast checked at - London Stock Exchange

Intraday Concurrent Technologies Share Chart

Product Launch

6 Apr 2010 11:26

Concurrent Technologies Plc

Product Launch New Computer Product Augments Competitive Position

Concurrent Technologies Plc ("Concurrent" or the "Company"), a world leading specialist in the design and manufacture of high-end embedded computer products, is pleased to announce the launch of a new range of VME embedded computer boards; the VP 717/08X.

This range of boards is based on the recently launched Intel® Coreâ„¢ i7 processor which has been introduced for the mobile embedded market and is based on the very latest 32nm technology. The processor introduces key features which will be of benefit to an even wider range of applications within the defence market than previously suited to Intel® processor technology. Consequently, VP 717/08X customers will benefit from improved performance per Watt of power, a sophisticated memory cache as well as much faster memory performance and improved graphics capability. Given the high performance and increased functionality of the Coreâ„¢i7, the boards are particularly well suited for CPU intensive processing applications within the defence, homeland security, industrial control, and transportation market sectors. Commercial and extended temperature versions are available today, and a compatible range of ruggedized, conduction-cooled or air-cooled versions will be available shortly.

Glen Fawcett, Managing Director, Concurrent Technologies, commented:

"Concurrent remains committed to producing products which will be available for many years and this is no exception. We only use processors from Intel's embedded roadmap which guarantees availability for a minimum of 7 years; this goes a long way to meeting the needs of our customers' requirements for long life cycle products while simultaneously providing them with enhanced processing capabilities.

The VP 717/08x, being an upgrade to an existing board,will appeal to both existing customers for technology refreshes, as well as new customers who can take advantage of the latest features of the Coreâ„¢ i7technology to standardize more of their application on Intel®based hardware, thereby reducing their overall cost of ownership."

6 April, 2010Enquiries:Concurrent Technologies Plc 01206 752 626

Glen Fawcett, Managing Director

Haggie Financial LLP 020 7417 8989

Nicholas Nelson

Nominated AdviserBrewin Dolphin Investment Banking 0845 213 4726

Neil Baldwin/Neil McDonald

All trademarks, registered trademarks and trade names used in this announcement are the property of their respective owners.

Note to Editors:

Concurrent Technologies Plc develops and manufactures high-end embedded computer products for use in a wide range of high performance applications within the telecommunications, defence, security, telemetry, scientific and aerospace markets. Using Intel® processors, including the latest Intel® Coreâ„¢ i7 processors, Intel® Xeon®, Atomâ„¢ and Coreâ„¢ 2 dual-core processors, the Company offers a wide range of computer products which are designed to be compliant with the most stringent industry specifications including those for products used in extremely harsh environments.

For more information on Concurrent and its products please visit http:// www.cct.co.uk

vendor
Date   Source Headline
20th Oct 20209:07 amRNSTreasury Shares
16th Oct 20207:00 amRNSIssue of Share Options and PDMR dealing
16th Oct 20207:00 amRNSTreasury Shares
6th Oct 20204:50 pmRNSTotal Voting Rights
11th Sep 20203:07 pmRNSDirector/PDMR Shareholding
2nd Sep 20207:00 amRNSInterim Results
21st Aug 20207:00 amRNSNotification of Interim Results
23rd Jul 202011:15 amRNSHolding(s) in Company
3rd Jul 20207:00 amRNSRetirement of Director
17th Jun 20202:33 pmRNSResult of AGM
16th Jun 20202:45 pmRNSAGM Statement
9th Jun 20205:17 pmRNSTotal Voting Rights & Director Shareholding
1st Jun 20207:00 amRNSHolding(s) in Company
29th May 20207:00 amRNSHolding(s) in Company
27th May 20204:55 pmRNSTotal Voting Rights & Director Shareholding
22nd May 20202:34 pmRNSPosting of Annual Report and Notice of AGM
22nd May 20207:00 amRNSDirector Appointment
12th May 20207:00 amRNSTotal Voting Rights
30th Apr 20206:18 pmRNSDirector/PDMR Shareholding
23rd Apr 20207:00 amRNSResults for the year ended 31 December 2019
17th Apr 20207:00 amRNSNotice of Results
26th Mar 20207:00 amRNSDirector Appointment and Results Timing Update
10th Mar 20207:00 amRNSSecond Interim Dividend
14th Feb 20206:06 pmRNSDirector/PDMR Shareholding
12th Feb 202012:18 pmRNSHolding(s) in Company
28th Jan 20207:00 amRNSProduct Announcement
24th Jan 20204:29 pmRNSHolding(s) in Company
21st Jan 20207:00 amRNSPost-Close Trading Update
7th Jan 20202:13 pmRNSHolding(s) in Company
7th Jan 20202:10 pmRNSHolding(s) in Company
6th Jan 202012:29 pmRNSHolding(s) in Company
20th Nov 201910:14 amRNSHolding(s) in Company
11th Oct 20191:45 pmRNSDirector/PDMR Shareholding
10th Sep 20197:00 amRNSInterim Results
9th Aug 20197:00 amRNSNotice of Interim Results
11th Jun 20198:45 amRNSProduct Announcement
22nd May 20194:41 pmRNSResult of AGM
21st May 20192:30 pmRNSAGM Statement
8th May 20197:00 amRNSDeath of Director
24th Apr 20197:00 amRNSDistribution of Annual Report and Accounts
4th Apr 20197:00 amRNSResults for the year ended 31 December 2018
29th Mar 20197:00 amRNSNotice of Results
14th Mar 20197:00 amRNSSecond Interim Dividend
6th Mar 20197:00 amRNSProduct Announcement
17th Jan 20192:50 pmRNSPost-Close Trading Update
14th Jan 20192:00 pmRNSLeave of Absence
8th Oct 20187:00 amRNSProduct Announcement
12th Sep 20187:00 amRNSInterim Results
6th Sep 20187:00 amRNSNotification of Interim Results
8th Jun 20187:00 amRNSProduct Announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.